Business Context and Reporting Period
This Form 6-K filing covers the month of May 2004 for Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata, but identified as Prana Biotechnology Limited in the filing text). The registrant is a foreign private issuer based in South Melbourne, Australia. The filing discloses changes in directors' interests pursuant to ASX Listing Rule 3.19A.2.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance disclosures regarding director shareholdings.
Material Changes
On January 12, 2004, three directors received ordinary shares in lieu of director fees totaling $40,000 each, pursuant to an AGM resolution dated December 17, 2003. The specific changes are:
- Brian Meltzer: Acquired 83,333 shares. Total holding increased to 243,333 shares (direct) and 300,000 options (indirect).
- Colin Masters: Acquired 83,333 shares. Total holding increased to 83,333 shares (direct) and 1,000,000 options (indirect).
- George Mihaly: Acquired 83,333 shares. Total holding increased to 83,333 shares (direct) and 300,000 options (indirect).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The only unusual item noted is the non-cash consideration (share issuance) used to settle director fees.
Investor Verification Checklist
- Verify the total number of shares issued to directors (249,999 total) against the company's capitalization table.
- Confirm the valuation of the shares issued to ensure the $40,000 fee per director aligns with the market price on the issuance date.
- Review the AGM resolution dated December 17, 2003, to understand the terms of the fee-for-share arrangement.
- Check subsequent filings for any changes in the directors' option holdings (300,000 to 1,000,000 options).